McQuade Center for Strategic Research and Development (MSRD)

Established in 2019 by Otsuka’s US Pharmaceutical Business, MSRD focuses on identifying and funding innovative early-stage research and development programs. The center aims to build Otsuka’s future product portfolio, particularly in areas of mental illness and renal disorders12.

MSRD collaborates with various organizations to develop novel treatments for complex and rare diseases. Recent collaborations include agreements with Mindset Pharma to develop psychedelic medicines and with Eikonizo Therapeutics to create treatments for amyotrophic lateral sclerosis (ALS) and other rare diseases.